These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

778 related items for PubMed ID: 19684472

  • 21. A pilot randomized study to assess immunogenicity, reactogenicity, safety and tolerability of two human papillomavirus vaccines administered intramuscularly and intradermally to females aged 18-26 years.
    Nelson EA, Lam HS, Choi KC, Ho WC, Fung LW, Cheng FW, Sung RY, Royals M, Chan PK.
    Vaccine; 2013 Jul 25; 31(34):3452-60. PubMed ID: 23770335
    [Abstract] [Full Text] [Related]

  • 22.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 23. Current prophylactic HPV vaccines and gynecologic premalignancies.
    Harper DM.
    Curr Opin Obstet Gynecol; 2009 Dec 25; 21(6):457-64. PubMed ID: 19923989
    [Abstract] [Full Text] [Related]

  • 24. Cellular immunogenicity of human papillomavirus vaccines Cervarix and Gardasil in adults with HIV infection.
    Zurek Munk-Madsen M, Toft L, Kube T, Richter R, Ostergaard L, Søgaard OS, Tolstrup M, Kaufmann AM.
    Hum Vaccin Immunother; 2018 Apr 03; 14(4):909-916. PubMed ID: 29172992
    [Abstract] [Full Text] [Related]

  • 25. Measurement of neutralizing serum antibodies of patients vaccinated with human papillomavirus L1 or L2-based immunogens using furin-cleaved HPV Pseudovirions.
    Wang JW, Jagu S, Wang C, Kitchener HC, Daayana S, Stern PL, Pang S, Day PM, Huh WK, Roden RB.
    PLoS One; 2014 Apr 03; 9(7):e101576. PubMed ID: 24999962
    [Abstract] [Full Text] [Related]

  • 26. Safety and immunogenicity of a 9-valent HPV vaccine in females 12-26 years of age who previously received the quadrivalent HPV vaccine.
    Garland SM, Cheung TH, McNeill S, Petersen LK, Romaguera J, Vazquez-Narvaez J, Bautista O, Shields C, Vuocolo S, Luxembourg A.
    Vaccine; 2015 Nov 27; 33(48):6855-64. PubMed ID: 26411885
    [Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28. [Vaccination against human papilloma virus and cervical cancer].
    Kidon MI, Shechter E, Toubi E.
    Harefuah; 2011 Jan 27; 150(1):33-6, 68. PubMed ID: 21449154
    [Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30. Safety and persistent immunogenicity of a quadrivalent human papillomavirus types 6, 11, 16, 18 L1 virus-like particle vaccine in preadolescents and adolescents: a randomized controlled trial.
    Reisinger KS, Block SL, Lazcano-Ponce E, Samakoses R, Esser MT, Erick J, Puchalski D, Giacoletti KE, Sings HL, Lukac S, Alvarez FB, Barr E.
    Pediatr Infect Dis J; 2007 Mar 27; 26(3):201-9. PubMed ID: 17484215
    [Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32. Human Papillomavirus neutralizing and cross-reactive antibodies induced in HIV-positive subjects after vaccination with quadrivalent and bivalent HPV vaccines.
    Faust H, Toft L, Sehr P, Müller M, Bonde J, Forslund O, Østergaard L, Tolstrup M, Dillner J.
    Vaccine; 2016 Mar 18; 34(13):1559-1565. PubMed ID: 26896686
    [Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34. An update of prophylactic human papillomavirus L1 virus-like particle vaccine clinical trial results.
    Schiller JT, Castellsagué X, Villa LL, Hildesheim A.
    Vaccine; 2008 Aug 19; 26 Suppl 10(Suppl 10):K53-61. PubMed ID: 18847557
    [Abstract] [Full Text] [Related]

  • 35. Immunogenicity and safety of Gardasil among mid-adult aged men (27-45 years)--The MAM Study.
    Giuliano AR, Isaacs-Soriano K, Torres BN, Abrahamsen M, Ingles DJ, Sirak BA, Quiterio M, Lazcano-Ponce E.
    Vaccine; 2015 Oct 13; 33(42):5640-5646. PubMed ID: 26343499
    [Abstract] [Full Text] [Related]

  • 36. Immunogenicity and safety of a bivalent, adjuvant system 04-adjuvanted human papillomavirus vaccine in healthy female volunteers aged 15-25: a randomized, double-blind, phase III, noninferiority clinical trial.
    Afshani SM, Mirhassani R, Hosseini H, Hosseini R, Tehranian A, Malekzadeh R, Ostovar A, Abdolghaffari AH, Ghobadi MA, Hedayatjoo B, Hazegh Fetratjoo D, Rezagholi Z, Anari A, Moini A.
    Eur J Cancer Prev; 2022 Nov 01; 31(6):558-567. PubMed ID: 35352698
    [Abstract] [Full Text] [Related]

  • 37. Safety and immunogenicity of Innovax bivalent human papillomavirus vaccine in girls 9-14 years of age: Interim analysis from a phase 3 clinical trial.
    Zaman K, Schuind AE, Adjei S, Antony K, Aponte JJ, Buabeng PB, Qadri F, Kemp TJ, Hossain L, Pinto LA, Sukraw K, Bhat N, Agbenyega T.
    Vaccine; 2024 Apr 02; 42(9):2290-2298. PubMed ID: 38431444
    [Abstract] [Full Text] [Related]

  • 38. Efficacy, immunogenicity and safety of the AS04-HPV-16/18 vaccine in Chinese women aged 18-25 years: End-of-study results from a phase II/III, randomised, controlled trial.
    Zhu FC, Hu SY, Hong Y, Hu YM, Zhang X, Zhang YJ, Pan QJ, Zhang WH, Zhao FH, Zhang CF, Yang X, Yu JX, Zhu J, Zhu Y, Chen F, Zhang Q, Wang H, Wang C, Bi J, Xue S, Shen L, Zhang YS, He Y, Tang H, Karkada N, Suryakiran P, Bi D, Struyf F.
    Cancer Med; 2019 Oct 02; 8(14):6195-6211. PubMed ID: 31305011
    [Abstract] [Full Text] [Related]

  • 39. The effect of a booster dose of quadrivalent or bivalent HPV vaccine when administered to girls previously vaccinated with two doses of quadrivalent HPV vaccine.
    Gilca V, Sauvageau C, Boulianne N, De Serres G, Crajden M, Ouakki M, Trevisan A, Dionne M.
    Hum Vaccin Immunother; 2015 Oct 02; 11(3):732-8. PubMed ID: 25714044
    [Abstract] [Full Text] [Related]

  • 40. Human papillomavirus vaccines.
    Schmiedeskamp MR, Kockler DR.
    Ann Pharmacother; 2006 Oct 02; 40(7-8):1344-52. PubMed ID: 16849621
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 39.